Biosimilar Patents in India – Patentability, Exclusivity and the Patent-Regulatory Interface
Biologics occupy a peculiar and increasingly central place in modern medicine large, complex molecules manufactured through living cell systems rather than chemical synthesis, used to treat cancer, autoimmune disease and a growing list of conditions for which no small-molecule alternative exists. As the patents covering the first generation of blockbuster biologics Herceptin, Avastin, Rituxan, Humira […]